GS Investments’s SAB Biotherapeutics SABS Stock Holding History

GS Investments’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$780	Hold	200	–	–	﹤0.01%	125
2026 Q1	$766	Hold	200	–	–	﹤0.01%	122
2025 Q4	$748	Hold	200	–	–	﹤0.01%	114
2025 Q3	$402	Hold	200	–	–	﹤0.01%	111
2025 Q2	$351	Hold	200	–	–	﹤0.01%	112
2025 Q1	$272	Hold	200	–	–	﹤0.01%	117
2024 Q4	$759	Hold	200	–	–	﹤0.01%	124
2024 Q3	$540	Hold	200	–	–	﹤0.01%	127
2024 Q2	$620	Hold	200	–	–	﹤0.01%	123
2024 Q1	$908	Hold	200	–	–	﹤0.01%	129
2023 Q4	$1.38K	Hold	200	–	–	﹤0.01%	124
2023 Q3	$1.26K	Hold	200	–	–	﹤0.01%	128
2023 Q2	$1.66K	Hold	200	–	–	﹤0.01%	130
2023 Q1	$880	Buy	+200	New	+$1.26K	﹤0.01%	144

Other funds holding SABS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GS Investments's SABS Position: Q2 2026 in Review

GS Investments held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 200 shares worth $780. The position accounts for ﹤0.01% of the portfolio, ranked #125.

GS Investments first reported a position in SABS in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.66K in Q2 2023. 49 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

GS Investments held 200 shares of SAB Biotherapeutics worth $780 as of Q2 2026.
GS Investments left its SAB Biotherapeutics share count unchanged in Q2 2026.
SAB Biotherapeutics made up ﹤0.01% of GS Investments's portfolio in Q2 2026, its #125 holding.
GS Investments first reported a position in SAB Biotherapeutics in Q1 2023 and has held it in 14 quarters since.
GS Investments's SAB Biotherapeutics position peaked at $1.66K in Q2 2023.
49 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on GS Investments's 13F filing for Q2 2026, filed 6 Aug 2026.